Farmácia/Notícias da Indústria

Estudo de caso controle e teste negativo | Efetividade da 4ª dose de vacina de mRNA contra Covid-19 causada pela variante Ômicron entre residentes de instituições de longa permanência em Ontário, Canadá.

8 Jul, 2022 | 11:30h

Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study – The BMJ

Estudo randomizado | Eficácia e segurança do upadacitinibe para espondilite anquilosante ativa refratária à terapia biológica.

8 Jul, 2022 | 11:15h

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial – Annals of Rheumatic Diseases

Comentário no Twitter

SELECT-AXIS 2 trial – patients with #AS and inadequate response to #bDMARDs. #RCT of upadacitinb vs placebo 14 weeks:
Improved signs and symptoms of active AS and was well tolerated for 14 weeks of treatment in bDMARD-IR patients!https://t.co/Z7fuxiXMDb pic.twitter.com/kGZX9AsaVE

— ARD & RMD Open (@ARD_BMJ) July 5, 2022

Análise post-hoc | Os inibidores de SGLT2 são capazes de reduzir o risco de nefrolitíase?

8 Jul, 2022 | 11:14h

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition? – The Journal of Clinical Endocrinology & Metabolism

Análise post-hoc | Os inibidores de SGLT2 são capazes de reduzir o risco de hiperuricemia e gota?

8 Jul, 2022 | 11:12h

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial – European Heart Journal

M-A | Efeitos cognitivos e neuropsiquiátricos do tratamento noradrenérgico na doença de Alzheimer.

8 Jul, 2022 | 11:07h

Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis – Journal of Neurology Neurosurgery & Psychiatry

Comentários:

Expert reaction to systematic review and meta-analysis looking at the evidence of whether noradrenergic drugs may be able to treat symptoms of Alzheimer’s disease – Science Media Centre

Noradrenergic drugs could be repurposed to offer effective treatment for Alzheimer’s disease symptoms – BMJ / News Medical

M-A | Anticoagulantes orais diretos vs. antagonistas da vitamina K em pacientes com fibrilação atrial com bioprótese de válvula cardíaca.

8 Jul, 2022 | 10:56h

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve – Frontiers in Cardiovascular Medicine

Revisão | O momento de hesitação da vacina.

7 Jul, 2022 | 12:21h

The Vaccine-Hesitant Moment – New England Journal of Medicine

Riscos específicos relacionados a idade e sexo para miocardite e pericardite após vacinação contra Covid-19 com vacinas de RNA mensageiro.

7 Jul, 2022 | 12:20h

Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines – Nature Communications

Estudo randomizado | Tratamento com odevixibate na colestase intra-hepática familiar progressiva.

7 Jul, 2022 | 12:11h

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial – The Lancet Gastroenterology & Hepatology

Invited Commentary: The first new drug for progressive familial intrahepatic cholestasis – The Lancet Gastroenterology & Hepatology (necessário cadastro gratuito)

Comentário no Twitter

New research – Thompson et al – Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial (PEDFIC 1)https://t.co/hPLmPLMcDt #livertwitter #cholestasis #PFIC pic.twitter.com/oUMMh1H0kv

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) July 1, 2022

Estudo randomizado | Enterosgel (polidrato de polimetilsiloxano) para tratamento da síndrome do intestino irritável com diarreia.

7 Jul, 2022 | 12:08h

Double-blinded randomised placebo controlled trial of enterosgel (polymethylsiloxane polyhydrate) for the treatment of IBS with diarrhoea (IBS-D) – Gut